Salvinorin A analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse

Advances in Pharmacology

Volumn 69, Issue , 2014, Pages 481-511

  Kivell, Bronwyn M ^a   Ewald, Amy W M ^a   Prisinzano, Thomas E ^b  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Addiction; Drug abuse; Kappa opioid receptor; Salvia divinorum; Salvinorin A

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; COCAINE; DITERPENE; DOPAMINE; DYNORPHIN; ENDORPHIN; ETHOXYMETHYL ETHER SALVINORIN B; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; METHOXYMETHYL ETHER SALVINORIN B; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; OPIATE; OPIATE RECEPTOR; PRODYNORPHIN; SALVINORIN A; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; COCAINE DEPENDENCE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; INFANCY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84893194258     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-420118-7.00012-3     Document Type: Chapter

References (167)

1. Acri J.B., Thompson A.C., Shippenberg T. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 2001, 39(4):343-350.
2. Avidorreiss T., Zippel R., Levy R., Saya D., Ezra V., Barg J., et al. Kappa-opioid receptor-transfected cell-lines-Modulation of adenylyl-cyclase activity following acute and chronic opioid treatments. FEBS Letters 1995, 361(1):70-74.
3. Baker L.E., Panos J.J., Killinger B.A., Peet M.M., Bell L.M., Haliw L.A., et al. Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology 2009, 203(2):203-211.
4. Beardsley P.M., Pollard G.T., Howard J.L., Carroll F.I. Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. Psychopharmacology 2010, 210(2):189-198.
5. Beguin C., Potuzak J., Xu W., Liu-Chen L.-Y., Streicher J.M., Groer C.E., et al. Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues. Bioorganic & Medicinal Chemistry Letters 2012, 22(2):1023-1026.
6. Belcheva M.M., Clark A.L., Haas P.D., Serna J.S., Hahn J.W., Kiss A., et al. mu and kappa opioid receptors activate ERK/MAPK via different protein kinase c isoforms and secondary messengers in astrocytes. Journal of Biological Chemistry 2005, 280(30):27662-27669.
7. 3H]dopamine uptake is similar in both the rat striatum and nucleus accumbens. European Journal of Pharmacology 1989, 173:215-217.
8. Bolan E.A., Kivell B., Jaligam V., Oz M., Jayanthi L.D., Han Y., et al. D-2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Molecular Pharmacology 2007, 71(5):1222-1232.
9. Braida D., Capurro V., Zani A., Rubino T., Vigano D., Parolaro D., et al. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia Divinorum, in rodents. British Journal of Pharmacology 2009, 157(5):844-853.
10. Braida D., Limonta V., Capurro V., Fadda P., Rubino T., Mascia P., et al. Involvement of kappa-opioid and endocannabinoid system on salvinorin A-induced reward. Biological Psychiatry 2008, 63(3):286-292.
11. Braida D., Limonta V., Pegorini S., Zani A., Guerini-Rocco C., Gori E., et al. Hallucinatory and rewarding effect of salvinorin A in zebrafish: Kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology 2007, 190(4):441-448.
12. Bruchas M.R., Land B.B., Aita M., Xu M., Barot S.K., Li S., et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. Journal of Neuroscience 2007, 27(43):11614-11623.
13. Bruchas M., Land B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Research 2010, 1314:44-55.
14. Bruchas M.R., Land B.B., Lemos J.C., Chavkin C. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS ONE 2009, 4(12):e8528.
15. Bruchas M.R., Schindler A.G., Shankar H., Messinger D.I., Miyatake M., Land B.B., et al. Selective p38 alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron 2011, 71(3):498-511.
16. Butelman E.R., Harris T.J., Kreek M.J. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 2004, 172(2):220-224.
17. Butelman E.R., Mandau M., Tidgewell K., Prisinzano T.E., Yuferov V., Kreek M.J. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. Journal of Pharmacology and Experimental Therapeutics 2007, 320(1):300-306.
18. Butelman E.R., Prisinzano T.E., Deng H., Rus S., Kreek M.J. Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: Fast onset and entry into cerebrospinal fluid. Journal of Pharmacology and Experimental Therapeutics 2009, 328(2):588-597.
19. Butelman E.R., Rus S., Prisinzano T.E., Kreek M.J. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: Dissociation from classic hallucinogen effects. Psychopharmacology 2010, 210(2):253-262.
20. Butelman E.R., Yuferov V., Kreek M.J. Kappa-opioid receptor/dynorphin system: Genetic and pharmacotherapeutic implications for addiction. Trends in Neurosciences 2012, 35(10):587-596.
21. Carlezon W.A., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. Journal of Pharmacology and Experimental Therapeutics 2006, 316(1):440-447.
22. Carlezon W.A., Thome J., Olson V.G., Lane-Ladd S.B., Brodkin E.S., Hiroi N., et al. Regulation of cocaine reward by CREB. Science 1998, 282(5397):2272-2275.
23. Carroll F.I., Carlezon W.A. Development of kappa-opioid receptor antagonists. Journal of Medicinal Chemistry 2013, 56(6):2178-2195. http://www.ncbi.nlm.nih.gov/pubmed/23360448.
24. Chartoff E.H., Potter D., Damez-Werno D., Cohen B.M., Carlezon W.A. Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 2008, 33(11):2676-2687.
25. Chartoff E., Sawyer A., Rachlin A., Potter D., Pliakas A., Carlezon W.A. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012, 62(1):167-176.
26. Chavkin C. The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology 2011, 36(1):369-370.
27. Chavkin C., James I.F., Goldstein A. Dynorphin is a specific endogenous ligand of the kappa-opioid receptor. Science 1982, 215(4531):413-415.
28. Chavkin C., Sud S., Jin W.Z., Stewart J., Zjawiony J.K., Siebert D.J., et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: Structural and functional considerations. Journal of Pharmacology and Experimental Therapeutics 2004, 308(3):1197-1203.
29. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. Journal of Neuroscience 2005, 25(20):5029-5037.
30. Chefer V.I., Moron J.A., Hope B., Rea W., Shippenberg T.S. Kappa-opioid receptor activation prevents alterations in mesocortical dopamine neurotransmission that occur during abstinence from cocaine. Neuroscience 2000, 101(3):619-627.
31. Chi L., Reith M.E. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. The Journal of Pharmacology and Experimental Therapeutics 2003, 307(2):729-736.
32. Collins S.L., D'Addario C., Izenwasser S. Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission. European Journal of Pharmacology 2001, 426(1-2):25-34.
33. Collins S.L., Kunko P.M., Ladenheim B., Cadet J.L., Carroll F.I., Izenwasser S. Chronic cocaine increases kappa-opioid receptor density: Lack of effect by selective dopamine uptake inhibitors. Synapse 2002, 45(3):153-158.
34. Daunais J.B., Roberts D.C.S., McGinty J.F. Cocaine self-administration increases preprodynorphin, but not c-fos, messenger-RNA in rat striatum. Neuroreport 1993, 4(5):543-546.
35. Dichiara G., Imperato A. Opposite effects of mu-opiate and kappa-opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. Journal of Pharmacology and Experimental Therapeutics 1988, 244(3):1067-1080.
36. Dykstra L., Gmerek D.E., Winger G., Woods J.H. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. Journal of Pharmacology and Experimental Therapeutics 1987, 242(2):413-420.
37. Ebner S.R., Roitman M.F., Potter D.N., Rachlin A.B., Chartoff E.H. Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology 2010, 210(2):241-252.
38. El Daly E., Chefer V., Sandill S., Shippenberg T.S. Modulation of the neurotoxic effects of methamphetamine by the selective kappa-opioid receptor agonist U69593. Journal of Neurochemistry 2000, 74(4):1553-1562.
39. Epling C., Jativa-M C.D. A new species of Salvia S. divinorum sp. nov. (Labiatae) from Mexico. Botanical Museum Leaflets, Harvard University 1962, 20(3):75-76.
40. Fagergren P., Smith H.R., Daunais J.B., Nader M.A., Porrino L.J., Hurd Y.L. Temporal upregulation of prodynorphin mRNA in the primate striatum after cocaine self-administration. European Journal of Neuroscience 2003, 17(10):2212-2218.
41. Furman C.A., Chen R., Guptaroy B., Zhang M., Holz R.W., Gnegy M. Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: Live-cell imaging using total internal reflection fluorescence microscopy. Journal of Neuroscience 2009, 29(10):3328-3336.
42. Gehrke B.J., Chefer V.I., Shippenberg T.S. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology 2008, 197(3):509-517.
43. Glick S.D., Maisonneuve I.M., Raucci J., Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Research 1995, 681:147-152.
44. Gramsch C., Hollt V., Pasi A., Mehraein P., Herz A. Immunoreactive dynorphin in human-brain and pituitary. Brain Research 1982, 233(1):65-74.
45. Grilli M., Neri E., Zappettini S., Massa F., Bisio A., Romussi G., et al. Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals. Neuropharmacology 2009, 57(5-6):523-530.
46. Groer C.E., Tidgewell K., Moyer R.A., Harding W.W., Rothman R.B., Prisinzano T.E., et al. An opioid agonist that does not induce mu-opioid receptor-Arrestin interactions or receptor internalization. Molecular Pharmacology 2007, 71(2):549-557.
47. Grundmann O., Phipps S.M., Zadezensky I., Butterweck V. Salvia divinorum and salvinorin A: An update on pharmacology and analytical methodology. Planta Medica 2007, 73(10):1039-1046.
48. Gulley J.M., Doolen S., Zahniser N.R. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. Journal of Neurochemistry 2002, 83(2):400-411.
49. Guo S., Zhou D.F., Sun H.Q., Wu G.Y., Haile C.N., Kosten T.A., et al. Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers. Psychopharmacology 2007, 190(4):449-456.
50. Hanes K.R. Antidepressant effects of the herb salvia divinorum: A case report. Journal of Clinical Psychopharmacology 2001, 21(6):634-635.
51. Harden M.T., Smith S.E., Niehoff J.A., McCurdy C.R., Taylor G.T. Antidepressive effects of the kappa-opioid receptor agonist salvinorin A in a rat model of anhedonia. Behavioural Pharmacology 2012, 23(7):710-715.
52. Heidbreder C.A., Babovicvuksanovic D., Shoaib M., Shippenberg T.S. Development of behavioral sensitization to cocaine-Influence of kappa-opioid receptor agonists. Journal of Pharmacology and Experimental Therapeutics 1995, 275(1):150-163.
53. Heidbreder C.A., Schenk S., Partridge B., Shippenberg T.S. Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist. Synapse 1998, 30(3):255-262.
54. Heyliger S.O., Jackson C., Rice K.C., Rothman R.B. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: Further evidence of kappa receptor heterogeneity. Synapse 1999, 34(4):256-265.
55. Hooker J.M., Patel V., Kothari S., Schiffer W.K. Metabolic changes in the rodent brain after acute administration of salvinorin A. Molecular Imaging and Biology 2009, 11(3):137-143.
56. Hooker J.M., Xu Y., Schiffer W., Shea C., Carter P., Fowler J.S. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. NeuroImage 2008, 41(3):1044-1050.
57. Horan P.J., Decosta B.R., Rice K., Haaseth R.C., Hruby V.J., Porreca F. Differential antagonism of bremazocine-induced and U69,593-induced antinociception by quadazocine-Further functional evidence of opioid kappa-receptor multiplicity in the mouse. Journal of Pharmacology and Experimental Therapeutics 1993, 266(2):926-933.
58. Hurd Y.L., Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993, 13(4):357-369.
59. Jackisch R., Hotz H., Hertting G. No evidence for presynaptic opioid receptors on cholinergic, but presence of kappa-receptors on dopaminergic-neurons in the rabbit caudate-nucleus-Involvement of endogenous opioids. Naunyn-Schmiedebergs Archives of Pharmacology 1993, 348(3):234-241.
60. Johnson M.W., MacLean K.A., Reissig C.J., Prisinzano T.E., Griffiths R.R. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence 2011, 115(1-2):150-155.
61. Killinger B.A., Peet M.M., Baker L.E. Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats. Pharmacology, Biochemistry, and Behavior 2010, 96(3):260-265.
62. Kivell B., Prisinzano T.E. Kappa opioids and the modulation of pain. Psychopharmacology 2010, 210(2):109-119.
63. Knoll A.T., Carlezon W.A. Dynorphin, stress, and depression. Brain Research 2010, 1314:56-73.
64. Koob G.F. A role for brain stress systems in addiction. Neuron 2008, 59(1):11-34.
65. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annual Review of Psychology 2008, 59:29-53.
66. Kreek M.J. Cocaine, dopamine and the endogenous opioid system. Journal of Addictive Diseases 1996, 15(4):73-96.
67. Land B.B., Bruchas M.R., Schattauer S., Giardino W.J., Aita M., Messinger D., et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(45):19168-19173.
68. Liu-Chen L.Y. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sciences 2004, 75(5):511-536.
69. Lovell K.M., Vasiljevik T., Araya J.J., Lozama A., Prevatt-Smith K.M., Day V.W., et al. Semisynthetic neoclerodanes as kappa opioid receptor probes. Bioorganic & Medicinal Chemistry 2012, 20(9):3100-3110.
70. Lozama A., Cunningham C.W., Caspers M.J., Douglas J.T., Dersch C.M., Rothman R.B., et al. Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A. Journal of Natural Products 2011, 74(4):718-726.
71. MacLean K.A., Johnson M.W., Reissig C.J., Prisinzano T.E., Griffiths R.R. Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects. Psychopharmacology 2013, 226(2):381-392.
72. Margolis E.B., Hjelmstad G.O., Bonci A., Fields H.L. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. Journal of Neuroscience 2003, 23(31):9981-9986.
73. Marinova Z., Vukojevic V., Surcheva S., Yakovleva T., Cebers G., Pasikova N., et al. Translocation of dynorphin neuropeptides across the plasma membrane-A putative mechanism of signal transmission. Journal of Biological Chemistry 2005, 280(28):26360-26370.
74. McCurdy C.R., Sufka K.J., Smith G.H., Warnick J.E., Nieto M.J. Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacology, Biochemistry, and Behavior 2006, 83(1):109-113.
75. McLennan G.P., Kiss A., Miyatake M., Belcheva M.M., Chambers K.T., Pozek J.J., et al. Kappa opioids promote the proliferation of astrocytes via G beta gamma and beta-arrestin 2-dependent MAPK-mediated pathways. Journal of Neurochemistry 2008, 107(6):1753-1765.
76. Mello N.K., Negus S.S. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1998, 286(2):812-824.
77. Mello N.K., Negus S.S. Interactions between kappa opioid agonists and cocaine. Preclinical studies. Annals of the New York Academy of Sciences 2000, 909:104-132.
78. Merg F., Filliol D., Usynin I., Bazov I., Bark N., Hurd Y.L., et al. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor. Journal of Neurochemistry 2006, 97(1):292-301.
79. Mitchell J.M., Liang M.T., Fields H.I. A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacology 2005, 182:384-392.
80. Morani A.S., Kivell B., Prisinzano T.E., Schenk S. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacology, Biochemistry, and Behavior 2009, 94(2):244-249.
81. Morani A.S., Schenk S., Prisinzano T.E., Kivell B.M. A single injection of a novel kappa opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behavioural Pharmacology 2012, 23(2):162-170.
82. Morani A.S., Ewald A., Prevatt-Smith K.M., Prisinzano T.E., Kivell B.M. The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats. European Journal of Pharmacology 2013, 720(1-3):69-76.
83. Mori T., Yoshizawa K., Ueno T., Nishiwaki M., Shimizu N., Shibasaki M., et al. Involvement of dopamine D2 receptor signal transduction in the discriminative stimulus effects of the kappa-opioid receptor agonist U-50,488H in rats. Behavioural Pharmacology 2013, 24(4):275-281.
84. Moron J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. Journal of Neuroscience 2003, 23(24):8480-8488.
85. Munro T.A., Duncan K.K., Xu W., Wang Y., Liu-Chen L.-Y., Carlezon W.A., et al. Standard protecting groups create potent and selective kappa opioids: Salvinorin B alkoxymethyl ethers. Bioorganic & Medicinal Chemistry 2008, 16(3):1279-1286.
86. Munro T.A., Rizzacasa M.A., Roth B.L., Toth B.A., Yan F. Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. Journal of Medicinal Chemistry 2005, 48(2):345-348.
87. Muschamp J.W., Carlezon W.A. Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. Cold Spring Harbor Perspectives in Medicine 2013, 3(2):a012005.
88. Muschamp J.W., Van't Veer A., Carlezon W.A. Tracking down the molecular substrates of stress: New roles for p38alpha MAPK and kappa-opioid receptors. Neuron 2011, 71(3):383-385.
89. Negus S.S., Mello N.K., Portoghese P.S., Lin C.E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1997, 282(1):44-55.
90. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nature Reviews. Neuroscience 2001, 2(2):119-128.
91. Nestler E.J., Carlezon W.A. The mesolimbic dopamine reward circuit in depression. Biological Psychiatry 2006, 59(12):1151-1159.
92. Nirenberg M.J., Chan J., Pohorille A., Vaughan R.A., Uhl G.R., Kuhar M.J., et al. The dopamine transporter: Comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. The Journal of Neuroscience 1997, 17:6899-6907.
93. Ortega A., Blount J.F., Manchand P.S. Salvinorin, a new trans-neoclerodane diterpene from Salvia divinorum (Labiatae). Journal of the Chemical Society, Perkin Transactions 1 1982, 2505-2508.
94. Peet M.M., Baker L.E. Salvinorin B derivatives, EOM-Sal B and MOM-Sal B, produce stimulus generalization in male Sprague-Dawley rats trained to discriminate salvinorin A. Behavioural Pharmacology 2011, 22(5-6):450-457.
95. Perreault M.L., Graham D., Scattolon S., Wang Y., Szechtman H., Foster J.A. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats. Psychopharmacology 2007, 194(4):485-496.
96. Pfeiffer A., Brantl V., Herz A., Emrich H.M. Psychotomimesis mediated by kappa-opiate receptors. Science 1986, 233(4765):774-776.
97. Picetti R., Schlussman S.D., Zhou Y., Ray B., Ducat E., Yuferov V., et al. Addictions and stress: clues for cocaine pharmacotherapies. Current Pharmaceutical Design 2013, 19(40):7065-7080.
98. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., Carlezon W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. The Journal of Neuroscience 2001, 21(18):7397-7403.
99. Porsolt R.D. Animal-model of depression. Biomedicine 1979, 30(3):139-140.
100. Potter D.N., Damez-Werno D., Carlezon W.A., Cohen B.M., Chartoff E.H. Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biological Psychiatry 2011, 70(8):744-753.
101. Prevatt-Smith K.M., Lovell K.M., Simpson D.S., Day V.W., Douglas J.T., Bosch P., et al. Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A. Medicinal Chemistry Communications 2011, 2(12):1217-1222.
102. Prisinzano T.E. Natural products as tools for neuroscience: Discovery and development of novel agents to treat drug abuse. Journal of Natural Products 2009, 72(3):581-587.
103. Prisinzano T.E., Rothman R.B. Salvinorin A analogs as probes in opioid pharmacology. Chemical Reviews 2008, 108(5):1732-1743.
104. Prisinzano T.E., Tidgewell K., Harding W.W. Kappa opioids as potential treatments for stimulant dependence. AAPS Journal 2005, 7(3):E592-E599.
105. Ranganathan M., Schnakenberg A., Skosnik P.D., Cohen B.M., Pittman B., Sewell R.A., et al. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biological Psychiatry 2012, 72(10):871-879.
106. Ronken E., Mulder A.H., Schoffelmeer A.N. Interacting presynaptic kappa-opioid and GABAA receptors modulate dopamine release from rat striatal synaptosomes. Journal of Neurochemistry 1993, 61(5):1634-1639.
107. Roth B.L., Baner K., Westkaemper R., Siebert D., Rice K.C., Steinberg S., et al. Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(18):11934-11939.
108. Rothman R.B., Dersch C.M., Carroll F.I., Ananthan S. Studies of the biogenic amine transporters. VIII: Identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse 2002, 43(4):268-274.
109. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., et al. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(12):6850-6855.
110. Schank J.R., Goldstein A.L., Rowe K.E., King C.E., Marusich J.A., Wiley J.L., et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addiction Biology 2012, 17:634-647.
111. 3H]WIN 35,428. The Journal of Pharmacology and Experimental Therapeutics 1991, 257:954-958.
112. Schenk S., Partridge B., Shippenberg T.S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology 1999, 144(4):339-346.
113. Schmidt M.D., Schmidt M.S., Butelman E.R., Harding W.W., Tidgewell K., Murry D.J., et al. Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synapse 2005, 58(3):208-210.
114. Shippenberg T.S. The dynorphin/kappa opioid receptor system: A new target for the treatment of addiction and affective disorders?. Neuropsychopharmacology 2009, 34(1):247.
115. Shippenberg T.S., Balskubik R., Herz A. Examination of the neurochemical substrates mediating the motivational effects of opioids-Role of the mesolimbic dopamine system and D-1 vs D-2 dopamine-receptors. Journal of Pharmacology and Experimental Therapeutics 1993, 265(1):53-59.
116. Shippenberg T.S., Bals-Kubik R., Huber A., Herz A. Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology 1991, 103(2):209-214.
117. Shippenberg T.S., Chefer V.I., Zapata A., Heidbreder C.A. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Annals of the New York Academy of Sciences 2001, 937:50-73.
118. Shippenberg T.S., Herz A. Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Research 1987, 436(1):169-172.
119. Shippenberg T.S., Herz A. Motivational effects of opioids: Influence of D-1 versus D-2 receptor antagonists. European Journal of Pharmacology 1988, 151(2):233-242.
120. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacology & Therapeutics 2007, 116(2):306-321.
121. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. Journal of Neurochemistry 2004, 90(5):1258-1268.
122. Siebert D.J. Salvia-divinorum and salvinorin-A-New pharmacological findings. Journal of Ethnopharmacology 1994, 43(1):53-56.
123. Simonin F., Gaveriaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., et al. Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proceedings of the National Academy of Sciences 1995, 92(15):7006-7010.
124. Sivam S.P. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. Journal of Pharmacology and Experimental Therapeutics 1989, 250(3):818-824.
125. Smiley P.L., Johnson M., Bush L., Gibb J.W., Hanson G.R. Effects of cocaine on extrapyramidal and limbic dynorphin systems. Journal of Pharmacology and Experimental Therapeutics 1990, 253(3):938-943.
126. Spanagel R., Herz A., Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(6):2046-2050.
127. Spangler R., Unterwald E.M., Kreek M.J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Molecular Brain Research 1993, 19(4):323-327.
128. Spangler R., Zhou Y., Maggos C.E., Schlussman S.D., Ho A., Kreek M.J. Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute "binge" cocaine. Brain Research. Molecular Brain Research 1997, 44(1):139-142.
129. Spencer R., Hruby V., Burks T. Body temperature response profiles for selective mu, delta and kappa opioid agonists in restrained and unrestrained rats. Journal of Pharmacology and Experimental Therapeutics 1988, 246(1):92-101.
130. Su D., Riley J., Kiessling W.J., Armstead W.M., Liu R. Salvinorin A produces cerebrovasodilation through activation of nitric oxide synthase, κ receptor, and adenosine triphosphate-sensitive potassium channel. Anesthesiology 2011, 114(2):374.
131. Suzuki T., Kishimoto Y., Ozaki S., Narita M. Mechanism of opioid dependence and interaction between opioid receptors. European Journal of Pain (London, England) 2001, 5:63-65.
132. Svingos A.L., Chavkin C., Colago E.E., Pickel V.M. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 2001, 42(3):185-192.
133. Tang A.H., Collins R.J. Behavioral-effects of a novel kappa-opioid analgesic, U-50488, in rats and rhesus-monkeys. Psychopharmacology 1985, 85(3):309-314.
134. Tao R., Auerbach S.B. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. Journal of Pharmacology and Experimental Therapeutics 2002, 303(2):549-556.
135. Tao R., Auerbach S.B. Mu-opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Research 2005, 1049(1):70-79.
136. Teksin Z.S., Lee I.J., Nemieboka N.N., Othman A.A., Upreti V.V., Hassan H.E., et al. Evaluation of the transport, in vitro metabolism and pharmacokinetics of salvinorin A, a potent hallucinogen. European Journal of Pharmaceutics and Biopharmaceutics 2009, 72(2):471-477.
137. Thompson A.C., Zapata A., Justice J.B., Vaughan R.A., Sharpe L.G., Shippenberg T.S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. Journal of Neuroscience 2000, 20(24):9333-9340.
138. Tidgewell K., Harding W.W., Schmidt M., Holden K.G., Murry D.J., Prisinzano T.E. A facile method for the preparation of deuterium labeled salvinorin A: Synthesis of [2,2,2-2H3]-salvinorin A. Bioorganic & Medicinal Chemistry Letters 2004, 14(20):5099-5102.
139. Tjon G.H.K., Voorn P., Vanderschuren L., DeVries T.J., Michiels N., Jonker A.J., et al. Delayed occurrence of enhanced striatal preprodynorphin gene expression in behaviorally sensitized rats: Differential long-term effects of intermittent and chronic morphine administration. Neuroscience 1997, 76(1):167-176.
140. Todtenkopf M.S., Marcus J.F., Portoghese P.S., Carlezon W.A. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 2004, 172(4):463-470.
141. Trifilieff P., Martinez D. Kappa-opioid receptor signaling in the striatum as a potential modulator of dopamine transmission in cocaine dependence. Frontiers in Psychiatry 2013, 4.
142. Tzaferis J.A., McGinty J.F. Kappa opioid receptor stimulation decreases amphetamine-induced behavior and neuropeptide mRNA expression in the striatum. Molecular Brain Research 2001, 93(1):27-35.
143. Unterwald E.M., Rubenfeld J.M., Kreek M.J. Repeated cocaine administration upregulates K and [mu], but not [delta], opioid receptors. Neuroreport 1994, 5(13):1613-1616.
144. Valdes L.J., Chang H.M., Visger D.C., Koreeda M. Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Organic Letters 2001, 3(24):3935-3937.
145. Van't Veer A., Carlezon W.A. Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology 2013, 1-18.
146. Vortherms T.A., Roth B.L. Salvinorin A: From natural product to human therapeutics. Molecular Interventions 2006, 6(5):257-265.
147. Walentiny D.M., Vann R.E., Warner J.A., King L.S., Seltzman H.H., Navarro H.A., et al. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology 2010, 210(2):275-284.
148. Walker B.M., Zorrilla E.P., Koob G.F. Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addiction Biology 2010, 16:116-119.
149. Walsh S.L., Geter-Douglas B., Strain E.C., Bigelow G.E. Enadoline and butorphanol: Evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. Journal of Pharmacology and Experimental Therapeutics 2001, 299(1):147-158.
150. Walsh S.L., Strain E.C., Abreu M.E., Bigelow G.E. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology 2001, 157(2):151-162.
151. Wang Y., Chen Y., Xu W., Lee D.Y.W., Ma Z., Rawls S.M., et al. 2-Methoxymethyl-salvinorin B is a potent kappa opioid receptor agonist with longer lasting action in vivo than salvinorin A. Journal of Pharmacology and Experimental Therapeutics 2008, 324(3):1073-1083.
152. Wang Z., Ma N., Riley J., Armstead W.M., Liu R. Salvinorin A administration after global cerebral hypoxia/ischemia preserves cerebrovascular autoregulation via kappa opioid receptor in piglets. PLoS ONE 2012, 7(7):e41724.
153. Wang Y.H., Sun J.F., Tao Y.M., Chi Z.Q., Liu J.G. The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacologica Sinica 2010, 31(9):1065-1070.
154. Wang X.M., Zhou Y., Spangler R., Ho A., Han J.S., Kreek M.J. Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Molecular Brain Research 1999, 66(1-2):184-187.
155. Watson S.J., Khachaturian H., Coy D., Taylor L., Akil H. Dynorphin is located throughout the CNS and is often co-localized with alpha-neo-endorphin. Life Sciences 1982, 31(16-1):1773-1776.
156. Wee S., Koob G.F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010, 210(2):121-135.
157. Wee S., Orio L., Ghirmai S., Cashman J.R., Koob G.F. Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology 2009, 205:565-575.
158. Weiss F., Markou A., Lorang M.T., Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Research 1992, 593(2):314-318.
159. Werling L.L., Frattali A., Portoghese P.S., Takemori A.E., Cox B.M. Kappa-receptor regulation of dopamine release from striatum and cortex of rats and guinea-pigs. Journal of Pharmacology and Experimental Therapeutics 1988, 246(1):282-286.
160. Winger G., Woods J.H. Comparison of fixed-ratio and progressive-ratio schedules of maintenance of stimulant drug-reinforced responding. Drug and Alcohol Dependence 1985, 15(1-2):123-130.
161. Wise R.A. Drug-activation of brain reward pathways. Drug and Alcohol Dependence 1998, 51(1-2):13-22.
162. Yasuda K., Raynor K., Kong H., Breder C.D., Takeda J., Reisine T., et al. Cloning and functional comparison of kappa-opioid and delta-opioid receptors from mouse-brain. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(14):6736-6740.
163. Yoshizawa K., Narita M., Saeki M., Narita M., Isotani K., Horiuchi H., et al. Activation of extracellular signal-regulated kinase is critical for the discriminative stimulus effects induced by U-50,488H. Synapse 2011, 65(10):1052-1061.
164. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., Kreek M.J. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology 2004, 172(4):422-429.
165. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., Kreek M.J. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: Agonist actions at kappa opioid receptors. Psychopharmacology 2005, 179(3):551-558.
166. Zhang Y., Schlussman S.D., Rabkin J., Butelman E.R., Ho A., Kreek M.J. Chronic escalating cocaine exposure, abstinence/withdrawal, and chronic re-exposure: Effects on striatal dopamine and opioid systems in C57BL/6J mice. Neuropharmacology 2013, 67:259-266.
167. Zhang H., Shi Y.G., Woods J.H., Watson S.J., Ko M.C. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: Behavioral and BDNF mRNA expression studies. European Journal of Pharmacology 2007, 570(1-3):89-96.